Literature DB >> 15126109

Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk.

Elif Akisik1, Nejat Dalay.   

Abstract

The estrogen receptor (ER) and the human epithelial growth factor receptor 2 (HER2) genes have been implicated in the development and prognosis of breast cancer. Several genetic polymorphic sites in these genes have been identified and associated with the risk of breast cancer. We have investigated the association between the estrogen receptor codon 594 (ACA to ACG) and HER2 codon 655 (ATC to GTC) polymorphisms and breast cancer risk. Genomic DNA from breast cancer patients and control subjects was analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). When allelic frequencies of the ER codon 594 and HER2 codon 655 gene were compared, no significant differences were observed between the patient and control groups. (P = 0.063, OR = 1.55, 95% CI = 0.25-9.41 and P = 0.949, OR = 1.01, 95% CI = 0.55-1.88, respectively). In conclusion, our results support the view that both the ER codon 594 and HER2 codon 655 polymorphisms are not associated with increased risk of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126109     DOI: 10.1016/j.yexmp.2003.12.005

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  9 in total

1.  Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.

Authors:  Patricia Rodrigues; Jessica Furriol; Eduardo Tormo; Sandra Ballester; Ana Lluch; Pilar Eroles
Journal:  Mol Cell Biochem       Date:  2013-04-06       Impact factor: 3.396

2.  Genetic variants of EGFR (142285G>A) and ESR1 (2014G>A) gene polymorphisms and risk of breast cancer.

Authors:  Ranbir Chander Sobti; Marjan Askari; Mohsen Nikbakht; Neha Singh; Suresh C Sharma; Abayneh Munshea Abitew
Journal:  Mol Cell Biochem       Date:  2012-07-19       Impact factor: 3.396

3.  Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients.

Authors:  N-Lale Satiroglu-Tufan; Ferda Bir; Nese Calli-Demirkan
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

4.  The polymorphism of EGFR 142285G > A exerts no risk effect on breast cancer.

Authors:  Qingcun Zheng; Ruiying Chen; Liqin Luan; Junrui Li; Suling Gao
Journal:  Tumour Biol       Date:  2013-10-28

5.  The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen.

Authors:  Nataliya Babyshkina; Sergey Vtorushin; Marina Zavyalova; Stanislav Patalyak; Tatyana Dronova; Nikolay Litviakov; Elena Slonimskaya; Julia Kzhyshkowska; Nadejda Cherdyntseva; Evgeny Choynzonov
Journal:  Clin Exp Med       Date:  2016-05-25       Impact factor: 3.984

6.  HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer.

Authors:  Oguz Ozturk; Emel Canbay; Ozlem T Kahraman; M Fatih Seyhan; Fatih Aydogan; Varol Celik; Cihan Uras
Journal:  Mol Biol Rep       Date:  2012-10-21       Impact factor: 2.316

Review 7.  No Association between Estrogen Receptor-Β Rs4986938 and Cancer Risk: A Systematic Review and Meta-Analysis.

Authors:  Zhaofang Li; Xiaoli Yang; Rongqiang Zhang; Dandan Zhang; Baorong Li; Di Zhang; Qiang Li; Yongmin Xiong
Journal:  Iran J Public Health       Date:  2019-05       Impact factor: 1.429

8.  Genetic polymorphisms in the EGFR (R521K) and estrogen receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia.

Authors:  Imen Kallel; Maha Rebai; Abdelmajid Khabir; Nadir R Farid; Ahmed Rebaï
Journal:  J Biomed Biotechnol       Date:  2009-07-14

9.  Her2 Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies.

Authors:  B Madhu Krishna; Sanjib Chaudhary; Aditya K Panda; Dipti Ranjan Mishra; Sandip K Mishra
Journal:  Sci Rep       Date:  2018-05-09       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.